

DSEX WENT DOWN BY 33.2 POINTS

Market closed negative today with increase in turnover.


Broad index DSEX went down by 33.2 points.

Only L. Insurance and Paper & Printing sectors closed positive today while Mutual Fund, Services & Real Estate and Food & Allied are the top three sectors that closed negative today.


Turnover increased by 3.3% to BDT 11,477mn (USD 93mn).

Textile sector dominated the turnover chart covering 20.8% of the total turnover.


Intraday Performance of DSEX




Sector Return



Sector P/E



52 Week Daily Turnover & DSEX



Index

Particulars	Value	Δ Points	Daily Δ %	Dec'25 Value	YTD Δ %
DSEX	5,860.96	(33.2)	-0.56%	4,865.34	20.46%
DS30	2,191.85	(9.9)	-0.45%	1,853.54	18.25%
DSES	1,180.71	(5.3)	-0.44%	1,000.72	17.99%
S&P 500	7,723.55	(13.0)	-0.17%	6,845.50	12.83%
Nikkei 225	65,683.26	(617.2)	-0.93%	50,339.48	30.48%
FTSE 100	10,928.06	39.8	0.37%	9,931.38	10.04%

Market Statistics

Particulars	Today	Last Day	Daily Δ	Daily Δ %	60 Day MA
Turnover (BDT mn)	11,477	11,115	362	3.26%	11,419
Turnover (USD mn)	93	90	3	3.26%	94
Volume (mn)	412	441	-29	-6.55%	382
Market Cap (BDT bn)	7,079	7,104	-25	-0.36%	
Market Cap (USD bn)	58	58	0	-0.36%	
Market P/E (x)	9.1				
Particulars	Gainer	Loser	Unchanged		
Market Breadth	88	263	41		

Sector Statistics

Sector	Market Cap (BDTmn)	% of total Market Cap	Sector Return	Turnover (BDTmn)	% of total Turnover
Bank	743,171	20.38%	-0.6%	660.5	5.75%
Pharma	598,993	16.43%	-0.3%	1,114.8	9.71%
Telecom	543,060	14.89%	-0.1%	96.6	0.84%
Engineering	311,936	8.55%	-0.6%	845.3	7.36%
Fuel & Power	309,754	8.49%	-0.5%	594.5	5.18%
Food & Allied	241,120	6.61%	-1.6%	367.5	3.20%
Textile	154,631	4.24%	-1.0%	2,389.8	20.82%
Misc	147,645	4.05%	-0.7%	534.2	4.65%
G. Insurance	128,427	3.52%	-0.7%	2,337.8	20.37%
NBFI	114,688	3.15%	-0.5%	363.8	3.17%
Cement	102,347	2.81%	-0.9%	57.0	0.50%
L. Insurance	54,927	1.51%	0.4%	406.1	3.54%
Travel & Leisure	37,504	1.03%	-1.3%	66.7	0.58%
IT	35,069	0.96%	-1.2%	404.8	3.53%
Mutual Fund	34,508	0.95%	-2.2%	586.0	5.11%
Services & Real Estate	28,432	0.78%	-1.7%	267.3	2.33%
Tannery	25,797	0.71%	-0.8%	90.7	0.79%
Paper & Printing	22,922	0.63%	0.4%	123.9	1.08%

Top Turnover

Ticker	Close Price (BDT)	Daily Δ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
SHARPIND	39.10	-6.01%	488.06	11.97	n/a
SIPLC	119.80	-7.92%	242.82	1.87	23.54
ACMEPL	26.00	-1.14%	237.86	9.12	n/a
SAPORTL	58.20	-2.35%	229.10	3.91	27.32
DOMINAGE	84.60	1.56%	209.75	2.54	n/a

Top Gainers

Ticker	Close Price (BDT)	Daily Δ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
NITOLINS	42.70	9.77%	72.26	1.70	21.24
TUNGHAI	3.60	9.09%	10.18	2.85	n/a
GBBPOWER	12.00	9.09%	31.76	2.67	120.00
SAMATALETH	109.70	7.76%	33.28	0.31	n/a
1STPRIMFMF	26.10	4.82%	45.39	1.76	30.71

Top Losers

Ticker	Close Price (BDT)	Daily Δ %	Turnover (BDTmn)	Volume (mn)	P/E (x)
SIPLC	119.80	-7.92%	242.82	1.87	23.54
PREMIERLEA	2.90	-6.45%	2.93	0.99	n/a
SHARPIND	39.10	-6.01%	488.06	11.97	n/a
CNATEX	3.20	-5.88%	2.57	0.78	n/a
QUEENSOUTH	18.80	-5.53%	116.28	6.03	235.00

BRACBANK

Earnings Disclosure Program on Half Yearly Financial Statements

The Company has informed that they will organize an earnings disclosure program on its Half Yearly Un-audited Financial Statements ended on June 30, 2026 on August 13, 2026 at 08:00 PM on a Digital Platform. The concerned Shareholders, Research Analysts and Financial Reporters are welcome to participate and ask questions at this event via live webcast facility at the web link: <https://meetbd.live/bracbankQ22026>. The company has also informed that questions may also be submitted via email to earningsdisclosure@bracbank.com on or by 04:00 PM of the above mentioned date. Name, Designation, Organization Name and Contact Number have to be included when sending the questions via email.

RENATA

Company exports first Therapeutics consignment to Portugal

The company has informed that it has expanded its presence in the European market by dispatching its first consignment of therapeutics to Portugal. The initial launch includes Amantadine 100 mg capsules, manufactured at EU-GMP-approved Rajendrapur General Facility, alongside Fludrocortisone 0.1 mg tablets & Cabergoline 0.5 mg tablets, produced at EU-GMP-approved Mirpur Potent Facility. This entry into Portugal represents a significant step in Renata's ongoing international expansion strategy across Europe.

Block Trade

Ticker	Max Price (BDT)	Min Price (BDT)	No. of Trades	Volume	Value (BDTmn)
ACIFORMULA	184.5	180	2	53500	9.855
AMANFEED	37.5	37.5	1	25000	0.938
AOL	18.8	18.8	1	31750	0.597
ASIATICLAB	129.1	128.9	5	347200	44.779
BBS	16.4	16.4	2	140500	2.304
BNICL	119	119	1	52000	6.188
BRACBANK	63	63	9	1760000	110.88
CAPITECGBF	11.2	11.2	1	50000	0.56
CITYGENINS	115	103.6	7	736504	83.613
DAFODILCOM	161.3	160	6	134501	21.552
DOMINAGE	82.5	77	18	892020	70.763
ETL	15.2	13	4	445800	5.94
FEKDIL	28.7	28.7	4	192711	5.531
FINEFOODS	435	435	2	5677	2.469
GENEXIL	36.8	36.8	1	18900	0.696
QGBALLPEN	530	530	1	12200	6.466
ICBSONALI1	7.7	7.7	1	100000	0.77
IPDC	34.4	28.8	6	2054998	67.68
ISLAMIINS	67.5	61	3	50800	3.18
ITC	52.8	51.8	2	40000	2.092
KARNAPHULI	50.4	50.4	2	400000	20.16
KAY&QUE	381	381	1	3030	1.154
MALEKSPIN	45.5	45.5	1	200000	9.1
MARICO	2700	2700	1	10000	27
MEGHNAPE	86	86	1	17322	1.49
MLDYEING	18	18	1	400000	7.2
MONNOFABR	25.3	25.3	1	67193	1.7
NPOLYMER	38.5	38.5	1	45000	1.732
PEOPLESINS	71	65	3	36350	2.513
PF1STMF	15.4	15.4	2	150000	2.31
PTL	68	66.8	2	16499	1.113
QUEENSOUTH	21	21	1	41000	0.861
RUNNERAUTO	48	44.5	2	50427	2.28
SAIHAMCOT	24.2	24.2	2	50000	1.21
SAIHAMTEX	26	26	1	139500	3.627
SEMLFBSLGF	8.9	8.9	1	61089	0.544
SIMTEX	26.8	26.8	1	40000	1.072
SIPLC	117.9	117.9	1	33813	3.987
SONARGAON	96.5	96.5	1	25000	2.413
SQURPHARMA	220.3	220	4	292000	64.27

Disclaimer

For U.S. persons only: This research report is a product of UCB Stock Brokerage Ltd. ("UCB"), a company authorized to engage in securities activities in Bangladesh, under Marco Polo Securities 15a-6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Research reports are intended for distribution by only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, UCB has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be affected through Marco Polo or another U.S. registered broker dealer.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by UCB Stock Brokerage Limited (UCB) with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of UCB and UCB accepts no liability whatsoever for the actions of third parties in this respect.

EQUITY RECOMMENDATION STRUCTURE (ABSOLUTE RATINGS)

We calculate our target price by weighting DCF, DDM, SOTP, asset-based and other relative valuation methods, and applying appropriate premiums/ discounts and/or other relevant adjustments.

Expected absolute returns are calculated as the % of difference between our target price and latest close price. Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Please note that future price fluctuations could lead to a temporary mismatch between upside/downside for a stock and our recommendation.

Recommendation Type	Holding period (if not otherwise mentioned)	Absolute Return Potential
Buy	12 Months	More than +15%
Neutral/ Hold	12 Months	Between -5% and +15%
Underweight	12 Months	Less than -5%

ANALYST CERTIFICATION

Respective analyst(s) identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report. The research analyst(s) named on this report are not registered / qualified as research analysts with FINRA.

It has not been determined in advance whether and in what intervals this document will be updated. Unless otherwise stated current prices refer to the most recent trading day's closing price.

Contact Us

Research Team

Md. Sakib Chowdhury, CFA	Head of Research	chowdhury.md.sakib@ucbstock.com.bd	+880 1713 205 698
Anik Mahmood Ibne Anwar, CFA	Deputy Head of Research	anik.mahmood@ucbstock.com.bd	+880 1701 205 074
Fahmid Islam Sadhin	Research Associate	fahmid.islam@ucbstock.com.bd	+880 1325 086 738
Numair M N Ahmmed	Research Associate	ahmmed.numair@ucbstock.com.bd	+880 1324 719 484
Kazi Rafi Hasan	Research Associate	kazi.rafi.hasan@ucbstock.com.bd	+880 1335 212 250
Md. Redwan Bin Rahman	Research Associate	redwan.bin.rahman@ucbstock.com.bd	+880 1712 733 003

Investment Strategist

Md. Hasib Reza, CFA	First Vice President	hasib.reza@ucbstock.com.bd	+880 1755 658 997
---------------------	----------------------	----------------------------	-------------------

Institutional & Foreign Trade

Tahmidur Rahman	First Assistant Vice President	rahman.tahmidur@ucbstock.com.bd	+880 1726 995 520
-----------------	--------------------------------	---------------------------------	-------------------

Office Premises

Head Office

Gulshan

Bulus Center

+880 2955 8481

Extensions of Head Office

Dilkusha +880 1701 205 090	Dilkusha (Sun Moon Tower) +880 1701 205 000	Dhanmondi +880 1713 205 703	Nikunja +880 1701 205 013	Mohammadpur +880 1324 243 212
Bashundhara +880 1718 106 217	Mirpur-1 +880 1713 205 723	Mirpur-12 +880 1911 197 188	Banasree +880 1701 205 075	Uttara +880 1913 128 156

Branch Offices

Chattogram +880 1701 205 038	Sylhet +880 1713 205 760
--	------------------------------------

Digital Booths

Khulna +880 1717 411 466	Barishal +880 1713 205 762	Cumilla +880 1324 243 163	Jashore +880 1324 243 203	Gazipur +880 1324 243 165
Feni +880 1324 243 210	Khatungonj +880 1713 205 742	Chawkbazar +880 1817 206 965	Madhobdi +880 1324 243 156	
	Narayangonj +880 1324 243 207	Agrabad +880 1324 243 198		